A practical reference on dual agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Hygroscopic, seal promptly after opening |
| Long-term storage temperature | At or below minus 20 C | Protect from repeated freeze-thaw |
| Working solution stability | Hours when refrigerated | Use within the same working day |
| Primary purity method | Reversed-phase HPLC | Often paired with mass spectrometry |
| Aggregate measurement | Size-exclusion chromatography | Reports high-molecular-weight species |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Those who have used topical corticosteroids over a prolonged period of time Those who have used corticosteroids to cover a large surface area Those with broken skin barrier or extensive abrasions Those who have recently undergone stress (such as illness, trauma, surgery) Children under the age of 12 HPA axis suppression is preventable by supplementation with glucocorticosteroids. If HPA axis suppression occurs, it is often reversed shortly after discontinuation of treatment.
=== June === 1 June – Robert Anderson, cricketer (Otago, Central Districts, national team) (born 1948). 4 June Edwin Perry, politician, New Zealand First list MP (2002–2005), Masterton District Councillor (2007–2010) (born 1948). Bruce Stewart, lawyer, Rhodes Scholar (1975), King's Counsel (since 2000) (born 1953). 6 June – Marise Wipani, beauty pageant contestant, actor (Came a Hot Friday, Shortland Street, Soldier Soldier), and television presenter (Lotto) (born 1964). 7 June – David Lean, local politician, Mayor of New Plymouth (1980–1992), Taranaki Regional Councillor (since 1989) (born 1948). 8 June Anthony Reid, historian (Australian National University, UCLA, National University of Singapore) (born 1939). Stu Wilson, rugby union player (Wellington, national team) and television commentator (born 1954). 10 June – Roka Ngarimu-Cameron, tohunga raranga and traditional Māori arts academic (University of Otago) (born 1948). 12 June Maurice Gee, novelist (Under the Mountain, In My Father's Den, Plumb), Arts Foundation of New Zealand Icon (since 2003) (born 1931). Phil Silva, psychologist and paediatrician (University of Otago), founder (1972) and director (1972–1999) of the Dunedin Study (born 1940). Sir Cliff Skeggs, Hall of Fame businessman and local politician, Mayor of Dunedin (1977–1989) (born 1931). 14 June – Lorraine Barry, music manager (Dave Dobbyn, Ice-T, Spice Girls) (born c. 1958). 15 June – Barry Vercoe, computer scientist (Massachusetts Institute of Technology) and composer, inventor of Csound (1985) (born 1937).
1333: Thomasia de Mattio, Italian physician, mentioned in Pope Sixtus IV edict regarding physicians and surgeons. fl. 1335: Polisena da Troya, licensed Neapolitan surgeon. d. 1366: Jeanne d'Ausshure, French surgeon. fl. 1374: Floreta La-Noga, Aragonese physician. fl. 1376: Virdimura of Catania, Jewish-Sicilian physician. fl. 1380: Bellayne Gallipapa, Zaragoza, Aragonese-Jewish physician. fl. 1384: Dolcich Gallipapa, Lleida, Catalan-Jewish physician. fl. 1384: Juana Sarrovia, Barcelona, Catalan physician. fl. 1387: Na Pla Gallipapa, Zaragoza, Aragonese-Jewish physician. late 13th century: Margherita di Napoli, Napolitan oculist active in Frankfurt-am-Main. fl. 1390: Dorotea Bucca, Italian professor of medicine. 1386–1408: Maesta Antonia, Florentine physician. 14th century: Abella, Italian physician. 14th century: Mercuriade, Italian physician and surgeon. fl. 1400: Antonia Daniello, Florentine-Jewish physician. fl. 13th century: Brunetta de Siena, Italian-Jewish physician. fl. 13th century: Caterina of Florence, Florentine physician. fl. 1411: Peretta Peronne, also called Perretta Petone, French surgeon. fl. 1415: Constance Calenda, Italian surgeon specializing in diseases of the eye. fl. 1438: Jeanne de Cusey, French barber-surgeon. fl. 1460: Marguerite Saluzzi, Napolitan licensed herbalist physician. fl. 1479: Guillemette du Luys, French royal surgeon. d. 1498: Gentile Budrioli (or Gentile Cimieri), Italian astrologer and herbalist. 15th century: Clarice di Durisio, Italian physician. 15th century Francesca, muller de Berenguer Satorra, Catalan physician. c.
Sources: en.wikipedia.org
Venom evolved just once among all Toxicofera about 170 million years ago, and then diversified into the huge venom diversity seen today. The original toxicoferan venom was a very simple set of proteins that were assembled in a pair of glands. Subsequently, this set of proteins evolved independently in the various lineages of toxicoferans, including Serpentes, Anguimorpha, and Iguania. Several snake lineages have since lost the ability to produce venom, often due to a change in diet or a change in predatory tactics. In addition to this, venom strength and composition has changed due to changes in the prey of certain snake species. For example, the venom of the marbled sea snake (Aipysurus eydouxii) became significantly less toxic after the diet of this species changed from fish to strictly fish eggs. The evolution of venom is thought to be responsible for the enormous expansion of snakes across the globe. The mechanism of evolution in most cases has been gene duplication in tissues unrelated to the venom. Pre-existing salivary proteins are the likely ancestors of most venom toxin genes. Expression of the new protein in the venom gland followed duplication. Then proceeded natural selection for adaptive traits following the birth-and-death model, where duplication is followed by functional diversification, resulting in the creation of structurally related proteins that have slightly different functions.
== Production and identity == Lymphocyte T-cell immunomodulator, or T-4 immune stimulating factor (TISF), is a single chain polypeptide that is a strongly cationic glycoprotein and is purified with cation exchange resin. Purification of protein from bovine-derived type II thymic epithelial cell supernatants produces a substantially homogeneous factor, free of extraneous materials. The bovine protein is homologous with other mammalian species and is a homogeneous 50 kDa glycoprotein with an isoelectric point of 6.5. The protein is prepared in a lyophilized 1 microgram dose. Reconstitution in sterile diluent produces a solution for subcutaneous injection. It is unknown what LTCI is in terms of its sequence. It is not interleukins 1-7 nor G-CSF. The manufacturer verifies its potency by checking for stimulation of IL-2 production.
== Tissue and subcellular localization == ACTH receptor is primarily found in the zona fasciculata of the human adrenal cortex. Binding of the receptor by ACTH stimulates the production of glucocorticoids (GCs)—by contrast, aldosterone production from the zona glomerulosa is stimulated primarily by angiotensin II. ACTH receptors are also expressed in the skin, and in both white and brown adipocytes, and is expressed in greater concentrations when adipose cells differentiate. It is well known that levels of corticosterone (CORT, cortisol in humans) secretion demonstrate a circadian rhythm, highly regulated by effects of the suprachiasmatic nucleus, with higher levels in the early evening and lower levels in the morning. ACTH levels, ACTH receptor expression, and MRAP1 expression also demonstrate circadian rhythm, with ACTH secretion and MRAP expression highest in the evening, suggesting that MRAP expression is responsible for CORT secretory regulation. However, with exposure to constant light, the rhythmic expression of the ACTH receptor and MRAP genes reversed, suggesting ACTH-independent signalling pathways for MRAP and ACTH receptor transcription and expression.
=== As collectables === Starfish are in some cases taken from their habitat and sold to tourists as souvenirs, ornaments, curios or for display in aquariums. In particular, Oreaster reticulatus, with its easily accessed habitat and bright coloration, is widely collected in the Caribbean. In the early to mid 20th century, this species was numerous along the West Indian coasts, but collection and trade have severely diminished its numbers. In the State of Florida, O. reticulatus is listed as endangered and its collection is illegal. Nevertheless, it is still sold both in and outside its range. A similar phenomenon exists in the Indo-Pacific for species such as Protoreaster nodosus.
Sources: en.wikipedia.org
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.
Reversed-phase high-performance liquid chromatography is the standard method for purity and related substances. It separates the main peak from deletion sequences and oxidation products. Mass spectrometry is frequently used alongside it to confirm molecular identity.
Aggregates, truncated sequences, and oxidation products receive the most attention. Size-exclusion chromatography covers aggregates, while reversed-phase methods resolve many chemical variants. Limits are set according to the route of administration and the expected exposure.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.